Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Cancer Research and Treatment ; : 88-91, 2007.
Artículo en Inglés | WPRIM | ID: wpr-195935

RESUMEN

Rituximab is a human/murine chimeric anti-CD20 mono- clonal antibody used to treat CD20-positive B-cell non- Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymp-tomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non- Hodgkin's lymphoma.


Asunto(s)
Humanos , Linfocitos B , Escalofríos , Quimioterapia , Fiebre , Rubor , Enfermedad de Hodgkin , Linfoma no Hodgkin , Neumonía , Piel , Rituximab
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA